Home - Products - GPCR/G Protein - Dopamine Receptor - Medifoxamine

Medifoxamine

CAS No. 32359-34-5

Medifoxamine( —— )

Catalog No. M34001 CAS No. 32359-34-5

Medifoxamine (LG 152) is a selective non-monoamine oxidase inhibitor that exhibits antidepressant activity through inhibition of 5 HT reuptake.Medifoxamine preferentially inhibits dopamine reuptake.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
2MG	152	Get Quote
5MG	235	Get Quote
10MG	353	Get Quote
25MG	615	Get Quote
50MG	864	Get Quote
100MG	1098	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Medifoxamine
Note

Research use only, not for human use.
Brief Description

Medifoxamine (LG 152) is a selective non-monoamine oxidase inhibitor that exhibits antidepressant activity through inhibition of 5 HT reuptake.Medifoxamine preferentially inhibits dopamine reuptake.
Description

Medifoxamine is a monoamine re-uptake inhibiting antidepressive agent which preferentially inhibits dopamine reuptake.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

GPCR/G Protein
Target

Dopamine Receptor
Recptor

Dopamine Receptor | Monoamine Oxidase
Research Area

——
Indication

——

Chemical Information

CAS Number

32359-34-5
Formula Weight

257.33
Molecular Formula

C16H19NO2
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 100 mg/mL (388.61 mM; Ultrasonic )
SMILES

CN(C)CC(Oc1ccccc1)Oc1ccccc1
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Saleh S, et al. Ocular hypotensive effects of medifoxamine. Br J Clin Pharmacol. 1992;34(3):269-271.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

CyPPA

CyPPA, a subtype-selective positive modulator of SK channels, decreased spontaneous firing rate, increased the duration of the apamin-sensitive afterhyperpolarization.
Tavapadon

Tavapadon (PF 6649751, PF-06649751) is an orally available dopamine D1 receptor partial agonist for treatment of Parkinson's disease.
Pramipexole

A partial/full agonist of dopamine receptor with Ki of 3.9/2.2/0.5/5.1 nM for D2S/D2L/D3/D4, respeectively.

Sign In Join Free